



Understanding Your Corus[®] CAD Score

Test Result Information for Patients






Coronary Artery Disease

Coronary Artery Disease (CAD) is the narrowing or blockage of the major blood vessels of your heart by cholesterol-containing deposits (plaque).

Obstructive CAD occurs when plaque blocks the majority of an opening of a coronary artery.

Corus[®] CAD is a blood test that helps your doctor safely assess the likelihood that you have obstructive CAD.



How the Corus CAD Test Works

Gene Expression Testing measures the activity of specific genes known to be involved in the disease process. The Corus CAD blood test uses age, sex, and gene expression to help your doctor assess your current likelihood of having obstructive CAD. This test is different than a genetic test which provides information about your future risk or predisposition. Your Corus CAD score can help your doctor quickly and conveniently rule out obstructive CAD.



What your Corus CAD Score Means

The Patient Score ranges from 1 to 40, with lower values associated with lower likelihood of a heart blockage, or obstructive Coronary Artery Disease (CAD).

In patients with low Corus CAD scores (1-15), 96% of patients do not have obstructive CAD¹.

PATIENT SCORE

Likelihood of Obstructive CAD*:

_____ %

Write in your Corus CAD score and likelihood of obstructive CAD.



Next Steps

Patients with low Corus CAD scores (1-15) have a low likelihood of having obstructive CAD.

For patients with non-low scores (16-40), further testing may be needed to determine whether your symptoms are due to obstructive CAD. Your doctor's recommendation is based on your Corus CAD score in combination with your symptoms, other test results, and risk factors.

Talk to your doctor to learn more about coronary artery disease and about how you can improve your heart health.

CardioDx®

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies.

Corus® CAD Intended Use

The Corus® CAD test is a quantitative in vitro diagnostic test performed in a single laboratory, using age, sex, and the gene expression profile of cells found in peripheral blood specimens to help a clinician identify the likelihood that a patient has coronary artery stenosis of at least 50%. The test should be performed on patients with a history of chest pain, with suspected anginal equivalent to chest pain, or with a high risk of coronary artery disease (CAD), but with no known prior myocardial infarction or revascularization procedures. The test is not intended for patients with acute myocardial infarction, high-risk unstable angina, systemic infectious or systemic inflammatory conditions, diabetes, or who are currently taking steroids, immunosuppressive agents, or chemotherapeutic agents.

The test is performed on a blood specimen obtained from the patient. The test incorporates age, sex, and the expression levels of multiple genes using an algorithm with weighted gene expression levels to generate a quantitative score. The results of the test should be used by clinicians in conjunction with other tests and clinical information when assessing a patient's CAD.

The Corus CAD test is for prescription use only. The test is not intended to be used to screen for stenosis among patients who are asymptomatic and not considered at high-risk for CAD, to predict or detect response to therapy, or to help select the optimal therapy for patients.

* Obstructive CAD is defined as at least one atherosclerotic plaque causing $\geq 50\%$ luminal diameter stenosis in a major coronary artery (≥ 1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or core-lab computed tomography angiography (CTA) (≥ 2.0 mm lumen diameter).

1. Thomas GS, Voros S, McPherson JA, et al. A Blood Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Non-Diabetic Patients Referred For Myocardial Perfusion Imaging: The COMPASS Study. *Circulation: Cardiovascular Genetics*. 2013;6(2):154-162.

CardioDx

600 Saginaw Drive
Redwood City, CA 94063
www.cardiodx.com

Customer Service

service@cardiodx.com
P 866.941.4996

Medical Affairs

medicalaffairs@cardiodx.com
P 866.941.4996